Avalyn Pharma Inc., (“Avalyn” or the “Company”), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, ...
A new systematic review and meta-analysis suggests that nerandomilast (Jascayd; Boehringer Ingelheim), an oral therapy for ...
Clinical Trials Arena on MSN
Avalyn initiates Phase II AURA trial for idiopathic pulmonary fibrosis
The study will enrol 160 patients with IPF who have not previously received treatment.
With receipt of inhaled treprostinil for 52 weeks, adults with idiopathic pulmonary fibrosis had less FVC decline compared ...
AGMB-447 is an investigational drug and not approved by any regulatory authority. Its efficacy and safety have not been established.
Emerging therapies, including inhaled and targeted treatments, could reshape care for progressive pulmonary fibrosis and address unmet patient needs.
While 80% of patients with pulmonary fibrosis find oxygen therapy beneficial, many face significant emotional and practical hurdles during initiation.
Immunomodulatory approaches such as GRI-0621 (RARβγ agonist targeting iNKT activity) may support alveolar basement membrane ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results